These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 28616718)
1. Effect of Intrastriatal 6-OHDA Lesions on Extrastriatal Brain Structures in the Mouse. Becker B; Demirbas M; Johann S; Zendedel A; Beyer C; Clusmann H; Haas SJ; Wree A; Tan SKH; Kipp M Mol Neurobiol; 2018 May; 55(5):4240-4252. PubMed ID: 28616718 [TBL] [Abstract][Full Text] [Related]
2. Characterization of graded 6-Hydroxydopamine unilateral lesion in medial forebrain bundle of mice. Cui J; Zhao D; Xu M; Li Z; Qian J; Song N; Wang J; Xie J Sci Rep; 2024 Feb; 14(1):3721. PubMed ID: 38355892 [TBL] [Abstract][Full Text] [Related]
3. Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus. Debeir T; Ginestet L; François C; Laurens S; Martel JC; Chopin P; Marien M; Colpaert F; Raisman-Vozari R Exp Neurol; 2005 Jun; 193(2):444-54. PubMed ID: 15869947 [TBL] [Abstract][Full Text] [Related]
4. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway. Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643 [TBL] [Abstract][Full Text] [Related]
5. Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response. Mendes-Pinheiro B; Soares-Cunha C; Marote A; Loureiro-Campos E; Campos J; Barata-Antunes S; Monteiro-Fernandes D; Santos D; Duarte-Silva S; Pinto L; José Salgado A Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768962 [TBL] [Abstract][Full Text] [Related]
6. Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat. Healy-Stoffel M; Omar Ahmad S; Stanford JA; Levant B Brain Res; 2014 Jul; 1574():113-9. PubMed ID: 24924804 [TBL] [Abstract][Full Text] [Related]
7. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease. Stott SRW; Barker RA Eur J Neurosci; 2014 Mar; 39(6):1042-1056. PubMed ID: 24372914 [TBL] [Abstract][Full Text] [Related]
8. Differential Effects of LPS and 6-OHDA on Microglia's Morphology in Rats: Implications for Inflammatory Model of Parkinson's Disease. Parra I; Martínez I; Ramírez-García G; Tizabi Y; Mendieta L Neurotox Res; 2020 Jan; 37(1):1-11. PubMed ID: 31478124 [TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Sleeman IJ; Boshoff EL; Duty S Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544 [TBL] [Abstract][Full Text] [Related]
10. Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair. Silva C; Fuxe K; Chadi G J Neural Transm Suppl; 2009; (73):185-202. PubMed ID: 20411778 [TBL] [Abstract][Full Text] [Related]
11. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI. Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909 [TBL] [Abstract][Full Text] [Related]
12. Prolonged Dysfunction of Astrocytes and Activation of Microglia Accelerate Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra and Block Compensation of Early Motor Dysfunction Induced by 6-OHDA. Kuter K; Olech Ł; Głowacka U Mol Neurobiol; 2018 Apr; 55(4):3049-3066. PubMed ID: 28466266 [TBL] [Abstract][Full Text] [Related]
13. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease. Stayte S; Rentsch P; Li KM; Vissel B PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062 [TBL] [Abstract][Full Text] [Related]
14. Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson's Disease in C57BL/6 Mice. Deng I; Corrigan F; Garg S; Zhou XF; Bobrovskaya L Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299000 [TBL] [Abstract][Full Text] [Related]
15. Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine. Rodrigues RW; Gomide VC; Chadi G Int J Neurosci; 2001 Jul; 109(1-2):91-126. PubMed ID: 11699344 [TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase. Mori MA; Delattre AM; Carabelli B; Pudell C; Bortolanza M; Staziaki PV; Visentainer JV; Montanher PF; Del Bel EA; Ferraz AC Nutr Neurosci; 2018 Jun; 21(5):341-351. PubMed ID: 28221817 [TBL] [Abstract][Full Text] [Related]
17. Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease. Ip CW; Beck SK; Volkmann J J Neural Transm (Vienna); 2015 Dec; 122(12):1633-43. PubMed ID: 26290125 [TBL] [Abstract][Full Text] [Related]